Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck says US court dismisses Vioxx class action
<p>The judge found that the securities action should be dismissed because all of the plaintiffs' claims were time-barred under the applicable statutes of limitations.<br /><br />The class action
<p>The judge found that the securities action should be dismissed because all of the plaintiffs' claims were time-barred under the applicable statutes of limitations.<br /><br />The class action
Reclast, which is marketed as Aclasta in some countries, is the first approved treatment for Paget’s disease patients to be given as a single-dose infusion compared to current
The study compared a 40mg dose of Copaxone given daily to the currently approved Copaxone 20mg dose. It was also designed to test the safety and tolerability of
Amgen had already said there was a higher death rate in preliminary data released in January. The overall number of deaths was greater in the Aranesp group at
The trial was designed to assess efficacy and safety with two doses of rotigotine, a dopamine agonist formulated as a patch for once-daily administration, in subjects with advanced
The phase I trial was conducted in 12 patients who underwent stereotactic neurosurgery to deliver the product, CERE-120, into their putamen, a region of the brain affected by
The trial is designed to establish the feasibility, safety and preliminary efficacy of vaccination in patients with recurrent, high-grade glioma, a fatal disease. Findings from a group of
The lawsuit was originally filed in August 2006 by Genzyme Corporation against Cytochroma, Proventiv Therapeutics LLC and three former Bone Care International employees. The complaint alleged misappropriation of
Patients treated with Renvela also achieved a significant reduction in calcium-phosphorus product and in LDL cholesterol. The drug was well tolerated with a safety profile consistent with the
The product is currently marketed by Laboratoires Thea in Europe under the brand name of Virgan. Sirion licensed the rights to Virgan for the US from Laboratoires Thea